AASLD 2022: Bulevirtide Safe, Effective at 72 Weeks for Hepatitis D-Related Compensated Cirrhosis
Virological and clinical responses increase over time, the authors say
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.